Pharmacologic treatment of emotional lability

Clinical Neuropharmacology
S Iannaccone, L Ferini-Strambi

Abstract

Emotional lability may be a part of the syndrome of pseudobulbar palsy. Here we report our experience with fluvoxamine, a selective serotonin reuptake inhibitor, used to treat 10 patients with emotional incontinence. Over a 7-month period, we studied and treated 10 consecutive patients (mean age, 61 +/- 8 years) attending our department: four had amyotrophic lateral sclerosis (progressive bulbar palsy form), four had clinically definite multiple sclerosis, and two had had strokes. They were given a single evening dose (100 mg) of fluvoxamine. All 10 patients had > 30 affective outbursts daily. It was observed that in 2 to 6 days, all the patients improved, the number of emotional outbursts dropping to none to five per day. This result suggests that the serotoninergic system may be implicated in emotional lability. The short latency of improvement we observed in our patients suggests that the mechanism of fluvoxamine for treating emotional lability differs from its mechanism for treating affective disorders.

Citations

Mar 20, 2001·Journal of Clinical Psychology·D C Mohr, D Cox
Aug 25, 2007·Current Treatment Options in Neurology·Hal S WortzelDavid B Arciniegas
Apr 20, 2010·Der Nervenarzt·P KraftK V Toyka
Dec 20, 2005·Journal of Neurology·J A RochaJ Mendes Ribeiro
Mar 30, 2006·Current Treatment Options in Neurology·Irene van Balken, Irene Litvan
Mar 13, 2008·Current Treatment Options in Neurology·Lisa S Thibodeaux, Amparo Gutierrez
Oct 8, 2013·European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society·Ditza A ZachorUNKNOWN Participants of Italian-Israeli Consensus Conference
Jun 5, 2003·Pharmacology & Therapeutics·Michael J Strong
Feb 21, 2002·Neurologic Clinics·G D BorasioR G Miller
May 3, 2007·Journal of Palliative Medicine·Lauren B ElmanLeo McCluskey
Sep 15, 2011·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies· Markus Weber
Jan 2, 2003·Postgraduate Medical Journal·R S Howard, R W Orrell
Nov 17, 2005·Clinical Practice and Epidemiology in Mental Health : CP & EMH·Stefano PallantiValentina Cesarali
Feb 3, 2004·Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases·Dallas A Forshew, Mark B Bromberg
Jun 16, 2009·European Journal of Internal Medicine·Sivakumar Sathasivam
Apr 25, 2006·Annals of Neurology·Hillel S PanitchUNKNOWN Psuedobulbar Affect in Multiple Sclerosis Study Group
Aug 28, 2007·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·P WicksL H Goldstein
Aug 16, 2016·Nature Reviews. Neurology·Esther V Hobson, Christopher J McDermott
Feb 24, 2001·Multiple Sclerosis : Clinical and Laboratory Research·R H BenedictL Jacobs
Jan 8, 1999·Acta Psychiatrica Scandinavica·K W BrownB Pentland
Dec 6, 2005·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·P M AndersenUNKNOWN EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis
Nov 3, 2006·Expert Review of Neurotherapeutics·Stephanie H Ameis, Anthony Feinstein
Jul 27, 2007·Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·Peter Munch AndersenUNKNOWN EALSC Working Group
May 5, 2011·Expert Review of Neurotherapeutics·Ariel MillerRandolph B Schiffer
Dec 9, 2004·Multiple Sclerosis : Clinical and Laboratory Research·Richard A SmithRonald A Thisted
Jan 1, 2014·Journal of Neurodegenerative Diseases·U E WilliamsS K Oparah

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

© 2021 Meta ULC. All rights reserved